FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983864341> ?p ?o ?g. }

• W1983864341 abstract "The incidence of renal cell cancer (RCC) has been increasing for the past decade, and the 5-year survival for patients with metastatic RCC (mRCC) is rather low. Everolimus (RAD001), a new inhibitor for mammalian target of rapamycin (mTOR), is generally well tolerated, and demonstrates clinical benefit to patients with anti-VEGF-refractory mRCC. However, factors for selection of patients who may benefit from everolimus remain largely unknown. Here we aimed to explore potential molecular indicators for mRCC patients who may benefit from everolimus treatment.Paraffin-embedded tumor tissue specimens derived from 18 mRCC patients before everolimus treatment, who participated the phase 1b trial of everolimus in VEGF receptor (VEGFR)-tyrosine kinase inhibitor (TKI)-refractory Chinese patients with mRCC (clinicaltrials.gov, NCT01152801), were examined for the expression levels of phosphorylated AKT, mTOR, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4EBP1) and 40S ribosomal protein S6 (S6RP) by immunohistochemistry. Clinical benefit rate (complete response [CR], partial response [PR], plus stable disease [SD] ≥ 6 months) and progression-free survival time (PFS) were correlated with expression levels of these mTOR-associated molecules.In these 18 patients, there were 1 PR, 15 SDs (including 9 SDs ≥ 6 months), and 2 progressive diseases (PD). The clinical benefit rate (CBR) was 55.6% (10/18), and the median PFS time was 8.4 months. Patients with positive expression of phospho-mTOR showed a better CBR (71.4% versus 0%, P = 0.023) and PFS time (11.3 versus 3.7 months, P = 0.001) than those patients with negative expression. The median PFS of patients with positive phospho-S6RP expression was longer (11.3 versus 3.7 months, P = 0.002) than that of patients negative for phospho-S6RP expression. However, expression levels of phospho-4EBP1 and phospho-AKT were unassociated to efficacy of everolimus treatment with respect to CBR and PFS. Co-expression of phosphorylated mTOR, S6RP and/or 4EBP1 may improve the predictive value of the biomarkers for patients treated with everolimus.The expression levels of phospho-mTOR and phospho-S6RP may be potential predictive biomarkers for efficacy of everolimus in patients with mRCC. Combining examinations of phosphorylated mTOR, S6RP and/or 4EBP1 may be a potential strategy to select mRCC patients sensitive to mTOR inhibitor treatment." @default.
• W1983864341 created "2016-06-24" @default.
• W1983864341 creator A5007562507 @default.
• W1983864341 creator A5009201250 @default.
• W1983864341 creator A5018372804 @default.
• W1983864341 creator A5034855042 @default.
• W1983864341 creator A5047883899 @default.
• W1983864341 creator A5055356574 @default.
• W1983864341 creator A5069813415 @default.
• W1983864341 date "2014-05-28" @default.
• W1983864341 modified "2023-10-02" @default.
• W1983864341 title "Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma" @default.
• W1983864341 cites W1964675052 @default.
• W1983864341 cites W1986308117 @default.
• W1983864341 cites W1987499203 @default.
• W1983864341 cites W2000110198 @default.
• W1983864341 cites W2016828438 @default.
• W1983864341 cites W2022201364 @default.
• W1983864341 cites W2036870740 @default.
• W1983864341 cites W2079183006 @default.
• W1983864341 cites W2079251713 @default.
• W1983864341 cites W2082563214 @default.
• W1983864341 cites W2097900396 @default.
• W1983864341 cites W2100468603 @default.
• W1983864341 cites W2103549763 @default.
• W1983864341 cites W2103799963 @default.
• W1983864341 cites W2105452584 @default.
• W1983864341 cites W2112519486 @default.
• W1983864341 cites W2118677643 @default.
• W1983864341 cites W2126022920 @default.
• W1983864341 cites W2138129102 @default.
• W1983864341 cites W2139248078 @default.
• W1983864341 cites W2147168993 @default.
• W1983864341 cites W2158734599 @default.
• W1983864341 cites W2164462432 @default.
• W1983864341 cites W4229808435 @default.
• W1983864341 doi "https://doi.org/10.1186/1471-2407-14-376" @default.
• W1983864341 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4041340" @default.
• W1983864341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24886512" @default.
• W1983864341 hasPublicationYear "2014" @default.
• W1983864341 type Work @default.
• W1983864341 sameAs 1983864341 @default.
• W1983864341 citedByCount "38" @default.
• W1983864341 countsByYear W19838643412014 @default.
• W1983864341 countsByYear W19838643412015 @default.
• W1983864341 countsByYear W19838643412016 @default.
• W1983864341 countsByYear W19838643412017 @default.
• W1983864341 countsByYear W19838643412018 @default.
• W1983864341 countsByYear W19838643412019 @default.
• W1983864341 countsByYear W19838643412020 @default.
• W1983864341 countsByYear W19838643412021 @default.
• W1983864341 countsByYear W19838643412022 @default.
• W1983864341 countsByYear W19838643412023 @default.
• W1983864341 crossrefType "journal-article" @default.
• W1983864341 hasAuthorship W1983864341A5007562507 @default.
• W1983864341 hasAuthorship W1983864341A5009201250 @default.
• W1983864341 hasAuthorship W1983864341A5018372804 @default.
• W1983864341 hasAuthorship W1983864341A5034855042 @default.
• W1983864341 hasAuthorship W1983864341A5047883899 @default.
• W1983864341 hasAuthorship W1983864341A5055356574 @default.
• W1983864341 hasAuthorship W1983864341A5069813415 @default.
• W1983864341 hasBestOaLocation W19838643411 @default.
• W1983864341 hasConcept C121608353 @default.
• W1983864341 hasConcept C126322002 @default.
• W1983864341 hasConcept C143998085 @default.
• W1983864341 hasConcept C204232928 @default.
• W1983864341 hasConcept C2777472916 @default.
• W1983864341 hasConcept C2777921159 @default.
• W1983864341 hasConcept C2779699572 @default.
• W1983864341 hasConcept C2780140570 @default.
• W1983864341 hasConcept C2781230642 @default.
• W1983864341 hasConcept C535046627 @default.
• W1983864341 hasConcept C55493867 @default.
• W1983864341 hasConcept C62478195 @default.
• W1983864341 hasConcept C71924100 @default.
• W1983864341 hasConcept C86554907 @default.
• W1983864341 hasConcept C86803240 @default.
• W1983864341 hasConceptScore W1983864341C121608353 @default.
• W1983864341 hasConceptScore W1983864341C126322002 @default.
• W1983864341 hasConceptScore W1983864341C143998085 @default.
• W1983864341 hasConceptScore W1983864341C204232928 @default.
• W1983864341 hasConceptScore W1983864341C2777472916 @default.
• W1983864341 hasConceptScore W1983864341C2777921159 @default.
• W1983864341 hasConceptScore W1983864341C2779699572 @default.
• W1983864341 hasConceptScore W1983864341C2780140570 @default.
• W1983864341 hasConceptScore W1983864341C2781230642 @default.
• W1983864341 hasConceptScore W1983864341C535046627 @default.
• W1983864341 hasConceptScore W1983864341C55493867 @default.
• W1983864341 hasConceptScore W1983864341C62478195 @default.
• W1983864341 hasConceptScore W1983864341C71924100 @default.
• W1983864341 hasConceptScore W1983864341C86554907 @default.
• W1983864341 hasConceptScore W1983864341C86803240 @default.
• W1983864341 hasIssue "1" @default.
• W1983864341 hasLocation W19838643411 @default.
• W1983864341 hasLocation W19838643412 @default.
• W1983864341 hasLocation W19838643413 @default.
• W1983864341 hasLocation W19838643414 @default.
• W1983864341 hasOpenAccess W1983864341 @default.
• W1983864341 hasPrimaryLocation W19838643411 @default.
• W1983864341 hasRelatedWork W1834745188 @default.

• next